Skip to main content

Advertisement

SpringerLink
Log in

Mycophenolate mofetil: a promising novel therapy in systemic sclerosis

  • Clinical Trials Report
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Steen VD, Conte C, Owens GR, Medsger TA Jr: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37: 1283–1289.

    Article  PubMed  CAS  Google Scholar 

  2. Bouros D, Wells AU, Nicholson AG, et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581–1586.

    Article  PubMed  Google Scholar 

  3. Wells AU, Hansell DM, Corrin B, et al.: High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992, 47:738–742.

    Article  PubMed  CAS  Google Scholar 

  4. Tashkin DP, Elashoff R, Clements PJ, et al.: Cyclophosphmide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655–2666.

    Article  PubMed  CAS  Google Scholar 

  5. Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993, 136:5–28.

    Article  PubMed  CAS  Google Scholar 

  6. Chan TM, Li FK, Tang CS, et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343:1156–1162.

    Article  PubMed  CAS  Google Scholar 

  7. Nowack R, Gobel U, Klooker P, et al.: Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999, 10:1965–1971.

    PubMed  CAS  Google Scholar 

  8. Schneider C, Gold R, Schafers M, Toyka KV: Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002, 25:286–288.

    Article  PubMed  CAS  Google Scholar 

  9. Tausche AK, Meurer M: Mycophenolate mofetil for dermatomyositis. Dermatology 2001, 202:341–343.

    Article  PubMed  CAS  Google Scholar 

  10. Swigris JJ, Olson AL, Fischer A, et al.: Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130:30–36.

    Article  PubMed  CAS  Google Scholar 

  11. Liossis SN, Bounas A, Andonopoulos AP: Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006, 45:1005–1008.

    Article  CAS  Google Scholar 

  12. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE: Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 2006, 45:1572.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Manu Jain MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Varga MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jain, M., Varga, J. Mycophenolate mofetil: a promising novel therapy in systemic sclerosis. Curr Rheumatol Rep 9, 133–135 (2007). https://doi.org/10.1007/s11926-007-0007-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0007-0

Keywords

Search

Navigation